Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
The Dashboard
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Type of publications
Guidelines (31)
NITAG documentation (1591)
Reports (55)
SAGE documentation (222)
Scientific publications (112)
Systematic reviews (SYSVAC) (2853)
Regions
Africa (274)
Americas (766)
Eastern Mediterranean (50)
Europe (705)
South-East Asia (81)
Western Pacific (199)
Diseases
Chikungunya (9)
Cholera (34)
COVID-19 (1513)
Cytomegalovirus (1)
Dengue (40)
Diphtheria (80)
Ebola (16)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (68)
Hepatitis A (64)
Hepatitis B (157)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (68)
HIV / AIDS (10)
Human papillomavirus (HPV) (493)
Influenza (581)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (28)
Measles (130)
Meningococcal disease (148)
Moraxella catarrhalis (1)
Mpox (55)
Mumps (46)
Pertussis (105)
Pneumococcal disease (277)
Poliomyelitis (86)
Q fever (1)
Rabies (29)
Rotavirus (117)
RSV (Respiratory syncytial virus) (48)
Rubella (64)
Salmonella (3)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (60)
Tick-borne encephalitis (12)
Tuberculosis (77)
Typhoid (24)
Varicella (69)
Yellow fever (42)
Zika (1)
Show more
4864 results found
2022
∙
ACIP
Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years
2022
∙
JCVI
JCVI interim advice on a single dose of HPV vaccine
2022
∙
JCVI
JCVI statement on COVID-19 vaccinations in 2022: 21 February 2022
2022
∙
JCVI
JCVI statement on the adult COVID-19 booster vaccination programme and the Omicron variant
2022
∙
JCVI
JCVI statement on vaccination of children aged 5 to 11 years old
2022
∙
JCVI
JCVI updated statement on the COVID-19 vaccination programme for autumn 2022
2022
∙
NIAC
Medium term strategy for the COVID-19 vaccination programme
2022
∙
SAGE
Modelled public health impact and cost effectiveness estimates of RTS,S/AS01 malaria vaccine in perennial and seasonal settings (August 2021)
2022
∙
NACI, Public Health Agency of Canada
NACI Rapid Response - Interim guidance on the use of Imvamune® in the context of monkeypox outbreaks in Canada
2022
∙
NACI
NACI Recommendations on the use of Medicago COVID-19 vaccine (Covifenz)
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register